Key result
The abstract discusses the rationale for protocol modifications regarding dextrothyroxine in the Coronary Drug Project without reporting specific quantitative results.
Why the study?
Does pharmacologic therapy of hyperlipidemia prevent CHD and prolong life in patients at risk for premature CHD?
Does pharmacologic therapy of hyperlipidemia prevent CHD and prolong life in patients at risk for premature CHD?
The report discusses the rationale and protocol modifications regarding dextrothyroxine in the Coronary Drug Project for the long-term treatment of hyperlipidemia to prevent CHD.
Answers are grounded in this paper and cite their sources.
Protocol modifications for dextrothyroxine signal safety concerns in hyperlipidemia therapy; leaves open whether such treatment prevents CHD.
As noted in the first definitive report from the Coronary Drug Project,1physicians face a difficult dilemma concerning pharmacologic therapy of hyperlipidemia in an attempt to prevent first or recurrent episodes of clinical coronary heart disease (CHD). They know that susceptibility to premature CHD is directly related to serum levels of cholesterol, and of low-density and very-low-density lipoproteins. They are also aware that elevated serum lipids-lipoproteins frequently can be reduced over long periods of time by available drugs. However, they lack answers to key questions about these pharmaceutical agents: Do they prevent CHD and prolong life? Are they reasonably safe in long-term usage? The scarcity of scientific data on these critical questions is especially troublesome in view of the fact that prevention or treatment of coronary disease by control of hyperlipidemia makes sense only as long-term therapy, and questions about drug toxicity are especially gnawing under this circumstance. The
No takes yet. Share an insight, caveat, or question.
A 1972 study studied Hyperlipidemia and coronary heart disease. Dextrothyroxine was evaluated. The abstract discusses the rationale for protocol modifications regarding dextrothyroxine in the Coronary Drug Project without reporting specific quantitative results.
Synapse has enriched 10 related papers. Consider them for comparative context: